Harvard Apparatus Regenerative Technology Secures $5M to Continue Clinical Trial
What You Should Know:
– Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a clinical-stage biotechnology company focused on developing organ regeneration technology for severe diseases, has secured approximately $5 million from a new investor through…
Continue Reading